> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# House Oversight Panel Puts Heat on FDA Over CBD
- URL: https://www.fdaweb.com/house-oversight-panel-puts-heat-on-fda-over-cbd/
- Published: 2023-04-18T12:00:00.000Z
- Updated: 2026-09-14T18:26:13.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5154235

House Committee on Oversight and Accountability chairman **James Comer** (R-KY) is putting pressure on FDA over its late January claim that it could not regulate cannabidiol (CBD) products as dietary supplements ([see earlier story](https://www.fdaweb.com/new-cbd-regulatory-framework-needed-woodcock/)). Comer sent a [4/14 letter](https://oversight.house.gov/wp-content/uploads/2023/04/Letter-to-FDA-re-Hemp-and-CBD.pdf?ref=fdaweb.com) to **Robert Califf** saying his committee is investigating the agency’s failure to regulate CBD and the potential this has in allowing dangerous products to come to market. The letter requests documents and information to enable oversight of FDA’s “failure to provide Americans with regulatory guidance,” the chairman says in a [release](https://oversight.house.gov/release/comer-fda-must-provide-americans-guidance-on-cbd-products%ef%bf%bc/?ref=fdaweb.com).

“FDA’s claim of a lack of a regulatory pathway is not only an insufficient rationale for inaction, but it is directly affecting the welfare of the American public,” Comer said. “Without allowing for therapeutic CBD products to be regulated as dietary supplements such as melatonin or fish oils, the good faith actors in the industry are unable to enter the market and provide people with helpful products because they are currently not distinguished under the FDA from the intoxicating products containing Delta-8\. It is imperative that the FDA engages in this regulation quickly, safely, and efficiently to provide proper guidance to the American people about the safety of CBD products.”

In January, FDA principal deputy commissioner **Janet Woodcock** said the agency had determined that current regulatory pathways are not appropriate for CBD and it will work with Congress on a new cross-agency regulatory framework. In a [statement](https://www.fda.gov/news-events/press-announcements/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol?ref=fdaweb.com), Woodcock says the need for a new framework was determined by a “high-level internal working group” that she chaired. Consistent with the statement describing the need for a new CBD framework, FDA also denied three citizen petitions that asked the agency to conduct rulemaking to allow the marketing of CBD products as dietary supplements.